Zebra Capital Management LLC Has $899,000 Stake in Corcept Therapeutics Incorporated (CORT)

Zebra Capital Management LLC reduced its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 8.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,179 shares of the biotechnology company’s stock after selling 5,567 shares during the period. Zebra Capital Management LLC’s holdings in Corcept Therapeutics were worth $899,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. Capital Fund Management S.A. grew its position in Corcept Therapeutics by 86.1% during the 2nd quarter. Capital Fund Management S.A. now owns 310,849 shares of the biotechnology company’s stock worth $4,887,000 after acquiring an additional 143,801 shares during the last quarter. Raymond James & Associates grew its position in Corcept Therapeutics by 20.1% during the 2nd quarter. Raymond James & Associates now owns 49,670 shares of the biotechnology company’s stock worth $781,000 after acquiring an additional 8,302 shares during the last quarter. Oak Ridge Investments LLC grew its position in Corcept Therapeutics by 33.6% during the 2nd quarter. Oak Ridge Investments LLC now owns 589,380 shares of the biotechnology company’s stock worth $9,265,000 after acquiring an additional 148,212 shares during the last quarter. Ingalls & Snyder LLC grew its position in Corcept Therapeutics by 7.3% during the 2nd quarter. Ingalls & Snyder LLC now owns 7,316,990 shares of the biotechnology company’s stock worth $115,023,000 after acquiring an additional 499,450 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its position in Corcept Therapeutics by 4.9% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,653,862 shares of the biotechnology company’s stock worth $25,999,000 after acquiring an additional 77,213 shares during the last quarter. Institutional investors own 74.79% of the company’s stock.

NASDAQ:CORT opened at $14.39 on Friday. Corcept Therapeutics Incorporated has a 52-week low of $11.55 and a 52-week high of $25.96. The firm has a market cap of $1.64 billion, a price-to-earnings ratio of 32.70 and a beta of 1.55.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.04). Corcept Therapeutics had a return on equity of 38.53% and a net margin of 68.32%. The firm had revenue of $62.31 million for the quarter, compared to analyst estimates of $68.49 million. During the same period in the prior year, the company posted $0.13 EPS. The firm’s quarterly revenue was up 75.2% compared to the same quarter last year. equities analysts expect that Corcept Therapeutics Incorporated will post 0.6 earnings per share for the current year.

A number of equities research analysts recently commented on CORT shares. B. Riley decreased their price target on Corcept Therapeutics from $30.00 to $22.00 and set a “buy” rating on the stock in a research report on Monday, August 13th. ValuEngine lowered Corcept Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, July 19th. Cantor Fitzgerald initiated coverage on Corcept Therapeutics in a report on Thursday, August 23rd. They set a “neutral” rating and a $17.00 price objective on the stock. BidaskClub downgraded Corcept Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. Finally, Zacks Investment Research downgraded Corcept Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $21.83.

In other news, insider Robert S. Fishman sold 8,000 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $14.57, for a total value of $116,560.00. Following the transaction, the insider now owns 8,000 shares of the company’s stock, valued at approximately $116,560. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director G Leonard Baker, Jr. purchased 179,686 shares of the business’s stock in a transaction dated Wednesday, August 15th. The stock was bought at an average cost of $12.48 per share, for a total transaction of $2,242,481.28. Following the purchase, the director now owns 876,838 shares in the company, valued at $10,942,938.24. The disclosure for this purchase can be found here. In the last three months, insiders bought 321,159 shares of company stock worth $4,025,880 and sold 24,000 shares worth $350,480. Corporate insiders own 15.00% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.

Featured Story: Stock Symbol

Want to see what other hedge funds are holding CORT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corcept Therapeutics Incorporated (NASDAQ:CORT).

Institutional Ownership by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply